Pesquisa Imagens Maps Play YouTube Notícias Gmail Drive Mais »
Fazer login
Usuários de leitores de tela: para usar o modo de acessibilidade, é preciso clicar neste link. O modo de acessibilidade tem os mesmos recursos básicos, mas funciona melhor com seu leitor de tela.

Patentes

  1. Pesquisa avançada de patentes
Número da publicaçãoEP0734396 B1
Tipo de publicaçãoConcessão
Número do pedidoEP19950904767
Número de PCT (Tratado de Cooperação em matéria de Patentes)PCT/US1994/013714
Data de publicação8 nov. 2000
Data de depósito28 nov. 1994
Data da prioridade17 dez. 1993
Também publicado comoCA2178218A1, DE69426270D1, DE69426270T2, EP0734396A1, US5550212, WO1995016707A1
Número da publicação1995904767, 95904767, 95904767.1, EP 0734396 B1, EP 0734396B1, EP-B1-0734396, EP0734396 B1, EP0734396B1, EP19950904767, EP95904767, PCT/1994/13714, PCT/US/1994/013714, PCT/US/1994/13714, PCT/US/94/013714, PCT/US/94/13714, PCT/US1994/013714, PCT/US1994/13714, PCT/US1994013714, PCT/US199413714, PCT/US94/013714, PCT/US94/13714, PCT/US94013714, PCT/US9413714
InventoresAndrew V. Schally, Marta Zarandi
RequerenteThe Administrators of The Tulane Educational Fund
Exportar citaçãoBiBTeX, EndNote, RefMan
Links externos:  Espacenet, EP Register
ANALOGUES OF hGH-RH (1-29)NH2 HAVING ANTAGONISTIC ACTIVITY
EP 0734396 B1
Resumo  (texto de WO1995016707A1)
Synthetic analogues of hGH-RH(1-29)NH2 having substitutions of various amino acids and acylated at the N-terminus, and exhibiting prolonged antagonistic duration. Embodiments include analogues of the formula: X-R<1>-R<2>-R<3>-R<4>-R<5>-R<6>-Thr-R<8>-Ser-Tyr-R<11>-R<12>-Val-Leu-R<15>-Gln-Leu-Ser-R<19>-R<20>-R<21>-Leu-Leu-Gln-Asp-Ile-R<27>-R<28>-R<29>, wherein X is nil, H, Ac, IAc, BrProp, For, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr or Aqc; R<1> is Tyr, His, Glu or Glt; R<2> is D-Arg, D-Cit, D-Har, D-Lys or D-Orn; R<3> is Asp, Ala or Gly; R<4> is Ala or Gly; R<5> is Ile, Ala or Gly; R<6> is Phe, Ala, Pro, Tpi, Nal or Phe(Y), in which Y is F, Cl, Br, NO2, CH3 or OCH3; R<8> is Asn, Ser, Val, Ile, Ala, Abu, Nle or Aib; R<11> is Arg, D-Arg or Cit; R<12> is Lys, D-Lys Cit or Ala; R<15> is Gly, Ala, Abu or Gln; R<19> is Ala or Abu; R<20> is Arg, D-Arg or Cit; R<21> is Lys, D-Lys or Cit; R<27> is Met, Nle or Abu; R<28> is Ser, Asn, Asp or Abu; R<29> is Agm, Arg-NH2, Arg-OH, Cit-NH2, Cit-OH, Har-NH2 or Har-OH; provided that when R<1> is Glt, X is nil and when X is H, R<15> is other than Gly, and pharmaceutically acceptable acid addition salts thereof.
Imagens(3)
Previous page
Next page
Reivindicações(30)
  1. A peptide having the formula :
    X-R1-R2-R3-R4-R5-R6-Thr-R8-Ser-Tyr-R11-R12-Val-Leu-R15-Gln-Leu-Ser-R19-R20-R21-Leu-Leu-Gln-Asp-Ile-R27-R28-R29
    Wherein
    X is H, Ibu, Nac, 2-Nac, 1-Npt, nil, Ac, IAc, BrProp, 1- or 2- Npr or Aqc
    R1 is Tyr, His, Glu or Glt,
    R2 is D-Arg or D-Cit
    R3 is Asp, Ala or Gly
    R4 is Ala or Gly,
    R5 is Ile, Ala or Gly,
    R6 is Phe, Ala, Pro, Tpi, Nal or Phe(Y) in which Y is F, Cl, Br, NO2, CH3, or 0CH3
    R8 is Asn, Ser, Val, Ile, Ala, Abu, Nle, or Aib,
    R11 is Arg, D-Arg or Cit,
    R12 is Lys, D-Lys, Cit or Ala
    R15 is Ala or Abu,
    R19 is Ala,
    R20 is Arg, D-Arg, or Cit,
    R21 is Lys, D-Lys or Cit,
    R27 is Nle or Abu,
    R28 is Ser, Asn, Asp or Abu, and
    R29 is Agm, Arg-NH2, Arg-OH, Cit-NH2, Cit-OH, Har-NH2 or Har-OH,
    provided that when R2 is D-Arg :
    X is H, Ibu, Nac, 2-Nac or 1-Npt, R1 is not Glt, R3 is Asp, R6 is Phe(pCl), Tpi, or Nal,
    R8 is Asn, R12 is Lys, R15 is Abu, R27 is Nle, R28 is Ser, and R29 is Agm or Arg-NH2,
    provided that when R2 is D-Cit :
    X is not 1- Npt,
    provided that when R2 is D-Cit and R1 is Glt:
    X is nil,
    and pharmaceutically acceptable acid addition salts thereof.
  2. A peptide according to claim 1 wherein R2 is D-Arg.
  3. A peptide according to claim 2 wherein R6 is Phe(pCl).
  4. A peptide according to claim 3 wherein X is Ibu or Nac, and R1 is Tyr or His.
  5. A peptide according to claim 4 wherein X is Nac, and R1 is Tyr.
  6. A peptide according to claim 4 wherein X is Ibu.
  7. A peptide according to claim 4 wherein R1 is His.
  8. A peptide according to claim 2 wherein X is Nac, R6 is Nal and R29 is Agm.
  9. A peptide according to claim 2 selected from the group consisting of peptides of the formula :
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCI)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile― Nle27―Ser―Arg―NH2,
    Nac0―His1-D-Arg2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln―Leu― Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile―Nle27― Ser―Arg―NH2 , and
    Ibu0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCI)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp― Ile―Nle27―Ser―Agm.
  10. A peptide according to claim 9 having the formula:
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile― Nle27―Ser―Arg―NH2.
  11. A peptide according to claim 9 having the formula :
    Nac0―His1-D-Arg2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln―Leu― Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile―Nle27― Ser―Arg―NH2.
  12. A peptide according to claim 9 having the formula :
    Ibu0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCI)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gin― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gin―Asp― Ile―Nle27―Ser―Agm.
  13. A peptide according to claim 2 selected from the group consisting of peptides of the formula :
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp― Ile―Nle27―Ser―Agm and
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Nal6―Thr―Asn― Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln―leu― Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile―Nle27― Ser―Agm
  14. A peptide according to claim 13 having the formula :
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp― Ile―Nle27―Ser―Agm
  15. A peptide according to claim 13 having the formula :
    Nac0―Tyr-D-Arg2―Asp―Ala―Ile―Nal6―Thr―Asn― Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln―Leu― Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp―Ile―Nle27― Ser―Agm
  16. A peptide according to claim 1 wherein R2 is D-Cit.
  17. A peptide according to claim 16 wherein X is Nac and R29 is Agm.
  18. A peptide according to claim 16 having the formula :
    Nac0―Tyr-D-Cit2―Asp―Ala―Ile―Phe(pCl)6―Thr― Asn―Ser―Tyr―Arg―Lys―Val―Leu―Abu15―Gln― Leu―Ser―Ala―Arg―Lys―Leu―Leu―Gln―Asp― Ile―Nle27―Ser―Agm.
  19. Use of a peptide according to one of claims 1-18 for preparing a medicament.
  20. Use of a peptide according to one of claims 1-18 for preparing a medicament for treating diabetic retinopathy.
  21. Use of a peptide according to one of claims 1-18 for preparing a medicament for treating diabetic nephropathy.
  22. Use of a peptide according to one of claims 1-18 for preparing a medicament for treating acromegaly.
  23. Use of a peptide according to one of claims 1-18 for preparing a medicament for treating mammalian cancers.
  24. Use according to claim 23 wherein the cancers are breast, lung, colon, brain and pancreatic cancers.
  25. Use according to claim 23 wherein the cancers are tumors having receptors for IGF-1 or being sensible to GH.
  26. Use of a peptide according to one of claims 1-18 for preparing a medicament for treating human osteosarcomas.
  27. A composition comprising a pharmaceutically effective amount of at least one peptide according to one of claims 1-18 in a pharmaceutically acceptable carrier.
  28. Products containing at least one peptide according to any one of claims 1-18 and at least one somatostatin analog as a combined preparation for use in cancer therapy.
  29. Use of a product according to claim 28 for preparing a medicament for treating mammalian cancers having IGF-1 receptors.
  30. Use according to claim 29 wherein the cancers are breast, lung, colon, brain and pancreatic cancers.
Descrição
  • [0001]
    The present invention relates to novel synthetic peptides which inhibit the release of growth hormone from the pituitary in mammals, and to therapeutic compositions containing these novel peptides.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Growth Hormone ("GH") is a peptide having 191 amino acids which stimulates the production of numerous different growth factors IGF-I and so promotes growth of numerous tissues (skeleton, connective tissue, muscle and viscera) and physiological activities (raising nucleic acid and protein synthesis and lipolysis, but lowering urea secretion).
  • [0003]
    Release of GH is under the control of releasing and inhibiting factors secreted by the hypothalamus. The primary releasing factor is growth hormone releasing hormone ("GH-RH"); human growth hormone-releasing hormone ("hGH-RH") is a peptide having 44 amino acids. The novel peptides of the present invention relate to analogues of hGH-RH having only residues 1 through 29 ("hGH-RH(1-29)NH2"), i.e., to analogues of the peptide which has the amino acid sequence:
    • Tyr-Ala-Asp-Ala-Ile5-Phe-Thr-Asn-Ser-Tyr10-Arg-Lys-Val-Leu-Gly15-Gln-Leu-Ser-Ala-Arg20-Lys-Leu-Leu-Gln-Asp25-Ile-Met-Ser-Arg29-NH2
  • [0004]
    GH has been implicated in several diseases. One disease in which GH is involved is acromegaly, in which excessive levels of GH are present. The abnormally enlarged facial and extremity bones of this disease can be treated by administering a GH-RH antagonist.
  • [0005]
    Further diseases involving GH are diabetic retinopathy and diabetic nephropathy. The damage to the retina and kidneys respectively in these diseases, believed to be due to GH, results in blindness or reduction in kidney function. This damage however can be prevented or slowed by administration of an effective GH-RH antagonist.
  • [0006]
    In an effort to intervene in these disease and other conditions, some investigators have attempted to control GH levels by using somatostatin, one inhibitor of GH release. However, somatostatin, if administered alone, does not suppress GH or IGF-I levels to a desired degree. If administered in combination with a GH-RH antagonist, somatostatin would improve suppression of IGF-I levels much better.
  • [0007]
    Other workers have investigated various modifications of GH-RH to elucidate the relationship of the structure of GH-RH to its activity in an effort to provide synthetic congeners with improved agonistic or antagonistic properties. (Synthesis may be by solid phase method, described in US Patent 4,914,189, or in liquid phase, as described in US Patent 4,707,541.) Thus, in one study, it was found that synthesizing GH-RH without its N-terminus residue -- i.e., forming hGH-RH(2-44) -- results in an analogue having GH releasing activity which is only 0.1 % that of GH-RH. By contrast, synthesizing a GH-RH analogue without its residues 30 through 44 -- i.e., synthesizing hGH-RH(1-29)NH2 -- results in an analogue which retains 50% or more of the potency of native hGH-RH. Synthesizing even shorter analogues -- e.g., GH-RH(1-28)NH2 or GH-RH(1-27)NH2 --resulted in substantially lower bioactivity. These results indicate that residues 1 and 29 are important to the bioactivity of GH-RH.
  • [0008]
    In another study, it was found that acetylating the N-terminus amino acid residue of GH-RH or replacing it with a D-isomer -- thus forming [Ac-Tyr1]GH-RH or [D-Tyr1]GH-RH-- lowers the ability of the analogues to release GH to 2-3% that of GH-RH. These analogues also have less affinity in vitro for GH-RH binding sites. By contrast, acetylation of the alpha amino group of residue 1 in hGH-RH(1-29)NH2 -- thus forming [AcTyr1]hGH-RH(1-29)NH2 -- is found to raise the in vivo potency over that of GH-RH by ten fold or more.
  • [0009]
    In further studies, it was found that [Ac-Tyr1,D-Arg2]hGH-RH(1-29) NH2 ant-agonizes the activation of rat anterior pituitary adenylate cyclase by hGH-RH(1-29)NH2. The same peptide was found to block the action of GH-RH on its receptors in the pituitary and hypothalamus, and to inhibit the pulsatile growth hormone secretion.
  • [0010]
    Several reported modifications to GH-RH have resulted in agonistic activity. US Patent 4,659,693 discloses agonists of hGH-RH(1-29) having the formula: R1-R2-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-R27-Ser-Arg-NH2,wherein R1 is H, Tyr or His; R2 may be various residues; and R27 is Nle. These agonists are said to stimulate release of growth hormone releasing factor ("GRF") and so to be suitable in pharmaceutical compositions. ("GRF" is merely a synonym for GH-RH, and the latter abbreviation is used hereinafter, despite use of GRF in US 4,659,693 and other publications.)
  • [0011]
    US Patent 4,914,189 discloses other analogues of GH-RH which are agonists. In these agonists, the N-terminus group Q1CO-, where Q1 signifies certain omega or alpha-omega substituted alkyl groups, may be Tyr or desamino-Tyr; the C-terminus group NH-Q2, where Q2 signifies certain lower omega-guanidino-alkyl groups, may be Agm; and R27 may be Nle. These analogues are said to be extremely potent stimulants of GH release and to enjoy high resistance to in vivo enzymatic degradation due to the omega-guanidino-lower alkyl group at the C-terminus.
  • [0012]
    Published application WO 91/16923 reviews earlier attempts to alter the secondary structure of hGH-RH by modifying its amino acid sequence. These earlier attempts include: replacing Tyr1, Ala2, Asp3 or Asn8 with their D-isomers; replacing Ser9 with Ala to enhance amphilicity of the region; and replacing Asn8 with L- or D-Ser, D-Arg, Asn, Thr, Gln or D-Lys. Certain of these modifications are said to enhance GH releasing activity. WO 91/16923 also states that replacing Asn8 with Ala induces an enormous increase in GH releasing activity. The peptides said to have this benefit have the formula: [R1,R2,Ala8,R15, Nle27]hGH-RH(1-29)-NH2, where R1 is Dat or A-R1, where A is lower acyl or benzyl and R1 includes Tyr and His; R2 is Ala, D-Ala or N-Me-D-Ala (N-Methyl-D-Ala); and R15 may include Gly, Ala or Aib. One preferred embodiment has R8,9,15 as Ala. It is noted that R8 in this publication is never Asn. Pharmaceutical compositions for enhancing growth are further disclosed.
  • [0013]
    European Patent Application Serial No. 0 413 839 A, filed August 22, 1989, assigned to the same assignee as the present application, discloses analogues of hGH-RH(1-29)-NH2 said to have enhanced release of GH. The analogues of this application replace residues 1, 2, 8, 12, 15, 27, 28 and 29 as follows: R1 may be Tyr or Dat; R2 may be L or D Ala; R8 may be Asn or Ser; R12 may be L or D isomers of Lys, Arg or Orn; R15 may be Gly or Ala; R27 may be Nle; R28 may be Asp, Asn or Ser; and R29 may be Agm. However, residue 6 is never replaced: it is always Phe.
  • [0014]
    Yet another modification of hGH-RH was disclosed in US Patent 5,183,660, where GH-RH was conjugated with polyethylene glycol derivatives. The resulting conjugate was said to exhibit decreased antigenicity, delay in biological clearance in vivo and physiological activity over a longer time.
  • [0015]
    In several of these investigations, it was found that variants of the hGH-RH agonistic analogues had antagonistic, rather than agonistic, activity. Thus, in US 4,659,693 (where R2 may be certain D-Arg residues substituted with alkyl groups), when R1 is H, the hGH-RH analogues are said to act as antagonists. Similarly, in WO 91/16923, discussed above, if R2 in the analogues is D-Arg, and R8, R9, and R15 are substituted as indicated above, antagonistic activity is said to result. These antagonistic peptides are said to be suitable for administration as pharmaceutical compositions to treat conditions associated with excessive levels of GH, e.g., acromegaly.
  • [0016]
    The antagonistic activity of the hGH-RH analogue "[Ser9-Ψ[CH2-NH]-Tyr10]hGH-RH(1-29)" of US Patent 5,084,555 was said to result from the pseudopeptide bond (i.e., a peptide bond reduced to a [CH2-NH] linkage) between the R9 and R10 residues. (It is noted that although this patent employed the seemingly redundant "Ψ[CH2-NH]" formula for the pseudo-peptide bond, actually only one such linkage had been introduced into the peptide.) However, the antagonistic properties of [Ser9-Ψ[CH2-NH]-Tyr10] hGH-RH(1-29) were said to be inferior to a conventional antagonist, [N-Ac-Tyr1, D-Arg2]GH-RH(1-29)-NH2.
  • SUMMARY OF THE INVENTION
  • [0017]
    There is provided a novel series of synthetic analogues of hGH-RH(1-29)NH2. These analogues inhibit the activity of endogenous hGH-RH, and therefore prevent the release of growth hormone. This inhibition is believed to result from replacement of various amino acids and acylation with aromatic or nonpolar acids at the N-terminus of GH-RH(1-29)NH2. The analogues exhibit prolonged antagonistic duration.
  • [0018]
    Specifically, the invention relates to peptides comprising the formula:
    • X-R1-R2-R3-R4-R5-R6-Thr-R8-Ser-Tyr-R11-R12-Val-Leu-R15-Gln-Leu-Ser-R19-R20-R21-Leu-Leu-Gln-Asp-Ile-R27-R28-R29
    Wherein
    • X is H, Ibu, Nac, 2-Nac, 1-Npt, nil, Ac, IAc, BrProp, 1- or 2- Npr or Aqc
    • R1 is Tyr, His, Glu or Glt,
    • R2 is D-Arg or D-Cit
    • R3 is Asp, Ala or Gly
    • R4 is Ala or Gly,
    • R5 is Ile, Ala or Gly,
    • R6 is Phe, Ala, Pro, Tpi, Nal or Phe(Y) in which Y is F, Cl, Br, NO2, CH3, or 0CH3
    • R8 is Asn, Ser, Val, Ile, Ala, Abu, Nle, or Aib,
    • R11 is Arg, D-Arg or Cit,
    • R12 is Lys, D-Lys, Cit or Ala
    • R15 is Ala or Abu,
    • R19 is Ala,
    • R20 is Arg, D-Arg, or Cit,
    • R21 is Lys, D-Lys or Cit,
    • R27 is Nle or Abu,
    • R28 is Ser, Asn, Asp or Abu, and
    • R29 is Agm, Arg-NH2, Arg-OH, Cit-NH2, Cit-OH, Har-NH2 or Har-OH,
      provided that when R2 is D-Arg :
    • X is H, Ibu, Nac, 2-Nac or 1-Npt, R1 is not Glt, R3 is Asp, R6 is Phe(pCl), Tpi, or Nal,
    • R8 is Asn, R12 is Lys, R15 is Abu, R27 is Nle, R28 is Ser, and R29 is Agm or Arg-NH2,
      provided that when R2 is D-Cit :
    • X is not 1-Npt,
      provided that when R2 is D-Cit and R1 is Glt:
    • X is nil,
    • and pharmaceutically acceptable acid addition salts thereof.
  • [0019]
    Among the preferred embodiments are peptides wherein X is Nac, or Ibu, R1 is Tyr or His, R2 is D-Arg or D-Cit, R3 is Asp, R4 is Ala, R5 is Ile, R6 is Phe(pCl) or Nal, R11 is Arg, R12 is Lys, R15 is Abu or Ala, R19 is Ala, R20 is Arg, R21 is Lys, R27 is Nle, R28 is Ser or Asp, and R29 is Agm or Arg-NH2. Three very preferred embodiments have the formulae:
    • Nac0-Tyr-D-Arg2-Asp-Ala-Ile-Phe(pCl)6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Agm ("Peptide 18")
    • Nac0-Tyr-D-Arg2-Asp-Ala-Ile-Nal6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Agm ("Peptide 32")
    • Nac0-Tyr-D-Cit2-Asp-Ala-Ile-Phe(pCl)6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Agm ("Peptide 34").
  • [0020]
    Under well-established convention, these may be abbreviated as follows:
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 18
    • [Nac0,D-Arg2,Nal6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 32
    • [Nac0,D-Cit2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 34
  • [0021]
    Four especially preferred embodiments have the formulae:
    • Nac0-Tyr-D-Arg2-Asp-Ala-Ile-Phe(pCl)6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Arg-NH2 ("Peptide 1")
    • Nac0-His1-D-Arg2-Asp-Ala-Ile-Phe(pCl)6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Arg-NH2 ("Peptide 5")
    • Ibu0-Tyr-D-Arg2-Asp-Ala-Ile-Phe(pCl)6-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu15-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle27-Ser-Agm ("Peptide 19").
  • [0022]
    These may be represented by well-accepted convention respectively as follows:
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 1
    • [Nac0,His1-D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 5
    • [Ibu0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 19
  • [0023]
    It is noted that the amino acid residues from 30 through 44 of the native GH-RH molecule do not appear to be essential to activity; nor does their identity appear to be critical. Therefore, it appears that the addition of some or all of these further amino acid residues to the C-terminus of the hGH-RH(1-29)-NH2 analogues of the present invention will not affect the efficacy of these analogues as GH antagonists. If some or all of these amino acids were added to the C-terminus of the hGH-RH(1-29)-NH2 analogues, the added amino acid residues could be the same as residues 30 through 44 in the native hGH-RH sequence or reasonable equivalents.
  • Synthetic Methods.
  • [0024]
    The synthetic peptides are synthesized by a suitable method such as by exclusive solid phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution phase synthesis.
  • [0025]
    When the analogues of this invention are synthesized by solid-phase method, the C-terminus residue (here, R29) is appropriately linked (anchored) to an inert solid support (resin) while bearing protecting groups for its alpha amino group (and, where appropriate, for its side chain functional group). After completion of this step, the alpha amino protecting group is removed from the anchored amino acid residue and the next amino acid residue, R28, is added having its alpha amino group (as well as any appropriate side chain functional group) suitably protected, and so forth. The N-terminus protecting groups are removed after each residue is added, but the side chain protecting groups are not yet removed. After all the desired amino acids have been linked in the proper sequence, the peptide is cleaved from the support and freed from any side chain protecting group(s) under conditions that are minimally destructive towards residues in the sequence. This is be followed by a careful purification and scrupulous characterization of the synthetic product, so as to ensure that the desired structure is indeed the one obtained.
  • [0026]
    It is particularly preferred to protect the alpha amino function of the amino acids during the coupling step with an acid or base sensitive protecting group. Such protecting groups should have the properties of being stable in the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain and without racemization of any of the chiral centers contained therein. Suitable alpha amino protecting groups are Boc and Fmoc.
  • Medical Applications.
  • [0027]
    The hGH-RH antagonist peptides, or salts of these peptides, may be formulated in pharmaceutical dosage forms containing effective amounts thereof and administered to humans or animal for therapeutic or diagnostic purposes. The peptides may be used to suppress GH levels and to treat conditions associated with excessive levels of GH, e.g., diabetic retinopathy and nephropathy, and acromegaly. The main uses of GH-RH antagonists are however,in the field of cancer, for example human cancers of the breast, lung, colon, brain, and pancreas where the receptors for IGF-I are present.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0028]
    • Figure 1 is a plot of tumor volumes in athymic nude mice bearing s.c. transplanted SK-ES-1 human sarcomas during treatment with Peptide 19 administered from osmotic minipumps at a dose of 40µg/animal/day. Treatment was started when the tumors measured approximately 33-39 mm3 and lasted for 4 and 3 weeks, respectively.
    • Figure 2 is a plot of tumor volumes in athymic nude mice bearing s.c. transplanted MNNG/HOS human sarcomas during treatment with Peptide 19 administered from osmotic minipumps at a dose of 40µg/animal/day. Treatment was started when the tumors measured approximately 33-39 mm3 and lasted for 4 and 3 weeks, respectively.
    • Figure 3 is a plot of the inhibitory effect of GH-RH antagonist Peptide 19 on growth of MXT estrogen independent mouse mammary cancer.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A. Abbreviations
  • [0029]
    The nomenclature used to define the peptides is that specified by the IUPAC-IUB Commissioner on Biochemical Nomenclature wherein, in accordance with conventional representation, the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right. The term "natural amino acid" as used herein means one of the common, naturally occurring L-amino acids found in naturally occurring proteins: Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met Phe, Tyr, Pro, Trp and His. When the natural amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented herein unless otherwise expressly indicated.
  • [0030]
    Non-coded amino acids, or amino acid analogues, are also incorporated into the GH-RH antagonists. ("Non-coded" amino acids are those amino acids which are not among the approximately 20 natural amino acids found in naturally occurring peptides.) Among the non-coded amino acids or amino acid analogues which may be used in the hGH-RH antagonist peptides are the following: by Abu is meant alpha amino butyric acid, by Agm is meant agmatine (1-amino-4-guanidino-butane), by Aib meant alpha amino isobutyric acid, by Har is meant homoarginine, by hPhe is meant homo-phenylalanine, by Nal is meant 2-naphthyl-alanine, and by Nle is meant norleucine. When these non-coded amino acids, or amino acid analogues, have isomeric forms, it is the L-form of the amino acid that is represented unless otherwise expressly indicated.
  • Abbreviations used herein are:
  • [0031]
    Abu
    α-aminobutyric acid
    Ac
    acetyl
    AcOH
    acetic acid
    Ac2O
    acetic anhydride
    Agm
    agmatine (1-amino-4-guanidino-butane)
    Aib
    α-aminoisobutyric acid
    Aqc
    anthraquinone-2-carbonyl
    BHA
    benzhydrylamine
    Boc
    tert.butyloxycarbonyl
    Bom
    benzyloxymethyl
    BOP
    benzotriazole-1-yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate
    BrProp
    bromopropionyl
    Bzl
    benzyl
    cHx
    cyclohexyl
    Cit
    citrulline, i.e.; 2-amino-5-ureidovaleric acid
    DCC
    dicyclohexylcarbodiimide
    DCM
    dichloromethane
    DIC
    N,N'-diisopropylcarbodiimide
    DIEA
    diisopropylethylamine
    DMF
    dimethylformamide
    Fmoc
    fluorenylmethyloxycarbonyl
    GH
    growth hormone
    GH-RH
    GH releasing hormone
    Glt
    glutaryl
    Har
    homoarginine
    hGH-RH
    human GH-RH
    HOBt
    1-hydroxybenzotriazole
    hPhe
    homophenylalanine
    HPLC
    high performance liquid chromatography
    IAc
    iodoacetyl
    Ibu
    isobutyryl
    MeOH
    methanol
    MeCN
    acetonitrile
    MBHA
    para-methylbenzhydrylamine
    Nac
    1-naphthylacetyl
    2-Nac
    2-naphthylacetyl
    Nal
    2-naphthyl-alanine
    Nle
    norleucine
    NMM
    N-methylmorpholine
    Npr
    naphthylpropionyl
    1-Npt
    1-naphthoyl
    2-Npt
    2-naphthoyl
    Phe(pCl)
    para-chloro-phenylalanine
    rGH-RH
    rat GH-RH
    RP-HPLC
    reversed phase HPLC
    SPA
    sulfophenoxy acetyl
    TFA
    trifluoroacetic acid
    Tos
    para-toluenesulfonyl
    Tpi
    2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-carboxylic acid
    Z
    benzyloxycarbonyl
    unsubstituted aromatic ring
  • B. The GH-RH Analogues
  • [0032]
    The hGH-RH analogues of the present invention were designed to increase the affinities of the peptides to the receptor, to improve metabolic stability and to maximize the amphophilic secondary structure of the molecules. Many of these analogues cause very effective and long lasting inhibition of GH release stimulated by hGH-RH(1-29)NH2.
  • [0033]
    The following embodiments are specially preferred as having remarkable bioactivity:
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 1
    • [Ibu0-His1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 3
    • [Nac0-His1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 5
    • [Ibu0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 7
    • [IAc0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 8
    • [Nac0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 9
    • [Ibu0-His1,D-Arg2,Tpi6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 10
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 18
    • [Ibu0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 19
    • [Nac0,D-Arg2,Nal6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 32
    • [Nac0,D-Cit2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 34
    • [D-Cit2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 35
    • [Nac0,D-Cit2,Nal6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 36
    • [D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 37
  • [0034]
    Three highly preferred embodiments have the following formulae:
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 18
    • [Nac0,D-Arg2,Nal6,Abu15,Nle22]hGH-RH(1-28)Agm   Peptide # 32
    • [Nac0,D-Cit2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 34
  • [0035]
    The most preferred embodiments have the following formulae:
    • [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 1
    • [Nac0-His1-D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide # 5
    • [Ibu0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide # 19
  • C. Method of Preparation 1. Overview of Synthesis.
  • [0036]
    The peptides are synthesized by a suitable method such as by exclusive solid phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution phase synthesis. For example, the techniques of exclusive solid-phase synthesis are set forth in the textbook "Solid Phase Peptide Synthesis", J.M. Stewart and J.D. Young, Pierce Chem. Company, Rockford, 111, 1984 (2nd. ed.), and M. Bodanszky, "Principles of Peptide Synthesis", SpringerVerlag, 1984. The hGH-RH antagonist peptides are preferably prepared using solid phase synthesis, such as that generally described by Merrifield, J.Am.Chem.Soc., 85, p. 2149 (1963), although other equivalent chemical syntheses known in the art can also be used as previously mentioned.
  • [0037]
    The synthesis is carried out with amino acids that are protected at their alpha amino group. Urethane type protecting groups (Boc or Fmoc) are preferably used for the protection of the alpha amino group. The preferred protecting group is Boc.
  • [0038]
    In solid phase synthesis, the moiety which forms the aminoacyl group of the final peptide at the C-terminus is attached to a polymeric resin support via a chemical link. After completion of the coupling reaction, the alpha amino protecting group is selectively removed to allow subsequent coupling reactions to take place at the amino-terminus, preferably with 50% TFA in DCM. The remaining amino acids with similarly Boc-protected alpha amino groups are coupled stepwise to the free amino group of the preceding amino acid on the resin to obtain the desired peptide sequence. Because the amino acid residues are added to the alpha amino group of the C-terminus residue, growth of the synthetic hGH-RH analogue peptides begins at the C terminus and progresses toward the N-terminus. When the desired sequence has been obtained, the peptide is acylated, if appropriate, and it is removed from the support polymer.
  • [0039]
    Each protected amino acid is used in excess (2.5 or 3 equivalents) and the coupling reactions are usually carried out in DCM, DMF or mixtures thereof. The extent of completion of the coupling reaction is monitored at each stage by the ninhydrin reaction. In cases where incomplete coupling is determined, the coupling procedure is repeated before removal of the alpha amino protecting group prior to the coupling of the next amino acid.
  • [0040]
    A typical synthesis cycle is shown in Table I.
    Protocol for a Typical Synthetic Cycle Using Boc-strategy
    Step (min) Reagent Mixing Time
    1. Deprotection 50% TFA in DCM
    5 + 25
    DCM wash 1
    2-propanol wash 1
    2. Neutralization 5% DIEA in DCM 1
    DCM wash 1
    MeOH wash 1
    5% DIEA in DCM 3
    MeOH wash 1
    DCM wash (3 times) 1-1
    3. Coupling 3 equiv. Boc-amino acid in DCM
    or DMF + 3 equiv. DIC or the preformed
    HOBt ester of the Boc-amino acid 60
    MeOH wash 2
    DCM wash 2
    MeOH wash 2
    DCM wash 2
    MeOH wash 2
    DCM wash 2
    4. Acetylation Ac2O in DCM (30%) 10
    + 20
    (if appropriate) MeOH wash (3 times) 2
    DCM wash (3 times) 2
  • [0041]
    After completion of the synthesis, the cleavage of the peptide from the resin can be effected using procedures well known in peptide chemistry.
  • [0042]
    Some of the amino acid residues of the peptides have side chain functional groups which are reactive with reagents used in coupling or deprotection. When such side chain groups are present, suitable protecting groups are joined to these functional groups to prevent undesirable chemical reactions from occurring during the reactions used to form the peptides. The following general rules are followed in selecting a particular side chain protecting group: (a) the protecting group preferably retains its protecting properties and is not split off under coupling conditions, (b) the protecting group should be stable to the reagent used in the coupling reaction conditions and in conditions for removing the alpha amino protecting group at each step of the synthesis and, (c) the side chain protecting group must be removable upon the completion of the synthesis of the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain.
  • [0043]
    The initial synthetic steps utilized herein are disclosed in US Patent 4,914,189. Reference is particularly made to Examples I through IV therein.
  • 2. Coupling R29 to the Support Polymer.
  • [0044]
    The hGH-RH antagonist peptides may be synthesized on a variety of support polymers. These support polymers may be amino resins such as amino-methyl resins, benzhydrylamine resins, p-methylbenzhydrylamine resins and the like. Boc-R29 is the initial material joined to the support phase, suitably Boc-Arg(Tos)-OH or Boc-Agm.
  • [0045]
    For the synthesis of peptides having Agm at the C-terminus, it is preferred that the support phase [SP] is an amino methyl resin. The guanidino group of Boc-Agm is joined to the support polymer via a stable but readily cleavable bridging group. It has been found that such a bridge may be readily provided by the sulfonyl phenoxy acetyl moiety. The alpha amino Boc-protected Agm is reacted with the chlorosulfonyl phenoxy acetic acid
       Cl-SO2--O-CH2-COOH to form
       Boc-Agm29-SO2--O-CH2-COOH.
  • [0046]
    This compound is then coupled to the support polymer [SP] using DIC or BOP as activating reagent to yield:
       Boc-Agm29-SO2--O-CH2-CO-[SP]
  • [0047]
    For the synthesis of peptides having Arg-NH2 at the C-terminus, Boc-Arg(Tos)-OH is coupled to the neutralized BHA or MBHA resin using DIC or BOP as activating reagent.
  • 3. Stepwise Coupling of Amino Acid Residues.
  • [0048]
    Utilizing the Boc-protected Agm resin (California Peptide Res. Inc.), (or the Boc-Arg(Tos)-resin), the peptide itself may suitably be built up by solid phase synthesis in the conventional manner. The selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as coupling reagents are N,N'-diisopropyl carbodiimide (DIC) or the BOP carboxyl activating reagent.
  • [0049]
    Each protected amino acid is coupled in about a three-fold molar excess, with respect to resin-bound aminoacyl residue(s), and the coupling may be carried out in as medium such as DMF: CH2Cl2 (1:1) or in DMF or CH2Cl2 alone. In cases where incomplete coupling occurs, the coupling procedure is repeated before removal of the alpha amino protecting group. The success of the coupling reaction at each stage of the synthesis is preferably monitored by the ninhydrin reaction.
  • 4. Removal of the Peptide from the Support Polymer.
  • [0050]
    When the synthesis is complete, the peptide is cleaved from the support phase. Removal of the peptide from the resin is performed by treatment with a reagent such as liquid hydrogen fluoride which also cleaves all remaining side chain protecting groups.
  • [0051]
    Suitably, the dried and protected peptide-resin is treated with a mixture consisting of 1.0 mL m-cresol and 10 mL anhydrous hydrogen fluoride per gram of peptide-resin for 60 min at 0°C to cleave the peptide from the resin as well as to remove all side chain protecting groups. After the removal of the hydrogen fluoride under a stream of nitrogen and vacuum, the free peptides are precipitated with ether, filtered, washed with ether and ethyl acetate, extracted with 50% acetic acid, and lyophilized.
  • 5. Purification
  • [0052]
    The purification of the crude peptides can be effected using procedures well known in peptide chemistry. For example, purification may be performed on a MacRabbit HPLC system (Rainin Instrument Co. Inc., Woburn, MA) with a Knauer UV Photometer and a Kipp and Zonen BD40 Recorder using a 10 x 250 mm VYDAC 228TP column packed with C8 silica gel (300 Å pore size, 10 µm particle size) (Rainin Inc.). The column is eluted with a solvent system consisting of (A) 0.1 % aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN in a linear gradient mode (e.g., 30-65% B in 120 min). The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph and pooled to give maximum purity. Analytical HPLC is carried out on a W-Porex C18 reversed-phase column (4.6 x 250 mm, 5 µm particle size, 300 Å pore size) (Phenomenex, Rancho Palos Verdes, CA) using isocratic elution with a solvent system consisting of (A) and (B) defined above. The peaks are monitored at 220 and 280 nm. The peptides are judged to be substantially (>95%) pure by analytical HPLC. The expected amino acid composition is also confirmed by amino acid analysis.
  • D. Pharmaceutical Composition
  • [0053]
    The peptides of the invention may be administered in the form of pharmaceutically acceptable, nontoxic salts, such as acid addition salts. Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, fumarate, gluconate, tannate, maleate, acetate, citrate, benzoate, succinate, alginate, pamoate, malate, ascorbate, tartarate, and the like. Particularly preferred antagonists are salts of low solubility, e.g., pamoate salts and the like. These exhibit long duration of activity.
  • [0054]
    The compounds of the present invention are suitably administered to subject humans or animals s.c., i.m., or i.v; intranasally or by pulmonary inhalation; or in a depot form (e.g., microcapsules, microgranules, or cylindrical rod like implants) formulated from a biodegradable suitable polymer (such as D,L-lactide-coglycolide), the former two depot modes being preferred. Other equivalent modes of administration are also within the scope of this invention, i.e., continuous drip, depot injections, infusion pump and time release modes such as microcapsules and the like. Administration is in any physiologically acceptable injectable carrier, physiological saline being acceptable, though other carriers known to the art may also be used.
  • [0055]
    The peptides are preferably administered parenterally, intramuscularly, subcutaneously or intravenously with a pharmaceutically acceptable carrier such as isotonic saline. Alternatively, the peptides may be administered as an intranasal spray with an appropriate carrier or by pulmonary inhalation. One suitable route of administration is a depot form formulated from a biodegradable suitable polymer, e.g., poly-D,L-lactide-coglycolide as microcapsules, microgranules or cylindrical implants containing dispersed antagonistic compounds.
  • [0056]
    The amount of peptide needed depends on the mode of administration and the intended result. In general, the dosage range is between 1-100 µg/kg of body weight of the host per day.
  • E. Therapeutic Uses of GH-RH Antagonists
  • [0057]
    hGH-RH antagonists can be used in treatment of conditions caused by excess growth hormone, for example acromegaly, which is manifested by an abnormal enlargement of the bones of the face and extremities. The GH-RH antagonists may also be used to treat diabetic retinopathy (the main cause of blindness in diabetics) and diabetic retinopathy, in which damage to the eye and kidney respectively is thought to be due to GH.
  • [0058]
    The hGH-RH antagonists are designed to block the binding and therefore the action of GH-RH, which stimulates the secretion of GH, which in turn stimulates production of IGF I. GH-RH antagonists may be administered alone or together with somatostatin analogues, a combination which more completely suppresses IGF-I levels. It is advantageous to administer antagonists of GH-RH rather than somatostatin due to the fact that GH-RH antagonists may be utilized in situations where target sites do not have somatostatin receptors.
  • [0059]
    However, the main applications of GH-RH antagonists are in the field of cancer. This is based on the following considerations: GH-RH antagonists are designed to block the binding and therefore the action of GH-RH, which stimulates the secretion of GH, which in turn stimulates production of insulin-like growth factor I(IGF-I) also called somatomedin-C. The involvement of IGF-I (somatomedin-C) in breast cancer, prostate cancer, colon cancer, bone tumors and other malignancies is well established, and somatostatin analogues alone do not adequately suppress GH and IGF-I levels. A complete suppression of IGF-I levels or secretion is required for a better inhibition of tumor growth. Autocrine production of IGF-I by various tumors could be also under control of GH-RH and might therefore be inhibited by GH-RH antagonists. GH-RH antagonists might also inhibit the production of IGF-I. A more detailed theoretical background of the applications of GH-RH in the field of oncology (cancer) is as follows: The receptors for IGF-I are present in primary human breast cancers , in lung cancers , in human colon cancers , in human brain tumors , and in human pancreatic cancers .
  • [0060]
    The presence of IGF-I receptors in these tumors appears to be related to malignant transformation and proliferations of these cancers. IGF-I can act as endocrine, paracrine or autocrine growth factor for various human cancers, that is the growth of these neoplasms is dependent on IGF-I. GH-RH antagonists by suppressing GH secretion would lower the production of IGF-I. Since IGF-I stimulates growth of these various neoplasms (cancers), the lowering of circulating IGF-I levels should lead to tumor growth inhibition. It is possible that GH-RH antagonists could also lower paracrine or autocrine production of IGF-I by the tumors, which should also lead to inhibition of cancer proliferation. These views are in accordance with modern concepts of clinical oncology. GH-RH antagonists should be given alone or together with somatostatin analogues and a combination would achieve a more complete suppression of IGF-I levels, elimination of tissue IGF-I levels, e.g., in human osteosarcomas, as well as breast cancer, colon cancer, prostate cancer, and non-small cell lung cancer (non-SCLC).
  • [0061]
    The advantage of GH-RH antagonists over somatostatin analogues is based on the fact that GH-RH antagonists may be utilized for suppression of tumors which do not have somatostatin receptors, for example human osteogenic sarcomas.
  • [0062]
    The present invention is described in connection with the following examples which are set forth for the purposes of illustration only.
  • [0063]
    The following Examples set forth suitable methods of synthesizing the novel GH-RH antagonists by the solid-phase technique.
  • EXAMPLE I Synthesis of Boc-agmatine EXAMPLE II Synthesis of 4-Chlorosulfonyl Phenoxyacetic Acid (Cl-SPA) EXAMPLE III Boc-agmatine-[SPA] EXAMPLE IV Coupling of Boc-agmatine-[SPA] to Support Phase
  • [0064]
    The initial synthetic sequence utilized herein and indicated by headings above is disclosed in Examples I through IV of US Patent 4,914,189.
  • EXAMPLE V
  • [0065]
    The synthesis of Peptide 1 having the formula:
    • Nac0-Tyr1-D-Arg2-Asp3-Ala4-Ile5-Phe(pCl)6-Thr7-Asn8-Ser9-Tyr10-Arg11-Lys12-Val13-Leu14-Abu15-Gln16-Leu17-Ser18-Ala19-Arg20-Lys21-Leu22-Leu23-Gln24-Asp25-Ile26-Nle27-Ser28-Arg29-NH2
    • or [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2
    is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Briefly, 4-methyl-benzhydrylamine (MBHA) resin (Bachem. California) (200 mg, 0.11 mmole) is neutralized with 5% DIEA in CH2Cl2 and washed according to the protocol described in Table I. The solution of Boc-Arg(Tos)-OH (141 mg, 0.33 mmole) in DMF-CH2Cl2 (1:1) is shaken with the neutralized resin and DIC (57 µL, 0.36 mmole) in a manual solid phase peptide synthesis equipment for 1 hour. After the completion of the coupling reaction is proved by negative ninhydrin test, deprotection with 50% TFA in CH2Cl2, and neutralization with 5% DIEA, the peptide chain is built stepwise by adding the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence:
    • Boc-Ser(Bzl)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Tyr(2,6-diCl-Z)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe(pCl)-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Arg(Tos)OH, and Boc-Tyr(2,6-diCl-Z)-OH.
  • [0066]
    These protected amino acid residues (also commonly available from Bachem Co.) are represented above according to a well accepted convention. The suitable protecting group for the side chain functional group of particular amino acids appears in parentheses. The OH groups in the above formulae indicate that each residue's carboxyl terminus is free.
  • [0067]
    The protected amino acids (0.33 mmole each) are coupled with DIC (57 µL, 0.36 mmole), with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. After removal of the Boc protecting group from the alpha amino group of Tyr1, the alpha amino group of Tyr1 is acylated. This is performed by the symmetrical anhydride method, in which 1-naphthylacetic acid (123 mg, 0.66 mmole) is reacted with DIC as an activating agent (60 µl, 0.37 mmole) to form a symmetric anhydride of 1-naphthylacetic acid. This symmetrical anhydride is reacted with the peptide.
  • [0068]
    In order to cleave the peptide from the resin and deprotect it, the dried peptide resin (325 mg) is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0°C for 1 hour. After evaporation of the HF under vacuum, the remnant is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50 % acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 145 mg crude product is obtained.
  • [0069]
    The crude peptide is checked by analytical HPLC using a Hewlett-Packard Model HP-1090 liquid chromatograph with a W-Porex C18 reversed-phase column (4.6 x 250mm, 5µm particle size, 300 Å pore size from Phenomenex, Rancho Palos Verdes, CA) and linear gradient elution, (e.g., 35-70% B) with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% TFA in 70% aqueous MeCN. 60 mg of the crude peptide is dissolved in AcOH/H2O), stirred, filtered and applied on a VYDAC 228TP column (10 x 250 mm) packed with C8 silica gel. The column is eluted with a solvent system described above in a linear gradient mode (e.g., 30-55% B in 120 min); flow rate 3mL/min. The eluent is monitored at 220 nm, and fractions are examined by analytical HPLC. Fractions with purity higher than 95% are pooled and lyophilized to give 3.5 mg pure product. The analytical HPLC is carried out on a W-Porex C18 reversed-phase column described above using isocratic elution with a solvent system described above with a flow rate of 1.2 mL/min. The peaks are monitored at 220 and 280 nm. Rt = 13.70 min and k' = 0.828 (isocratic elution with 52% B). The peptides are judged to be substantially (>95%) pure by analytical HPLC. The expected amino acid composition is also confirmed by amino acid analysis.
  • [0070]
    Peptides 3 and 5 are synthesized in the same manner as Peptide 1, except that Boc-Tyr(2,6-diCl-Z)-OH1 is replaced with Boc-His(Bom)-OH1 (0.33 mmole) and the resulting peptides are acylated with the appropriate anhydrides of isobutyric acid or 1-naphthylacetic acid respectively, to yield:
    • [Ibu0-His1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 3
    • [Nac0-His1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 5
  • [0071]
    Peptides 7, 8 and 9 are synthesized in the same manner as Peptide 1 except that Boc-Tyr(2,6-diCl-Z)-OH1 is replaced by Boc-Glu(OcHx)-OH1 (0.33 mmole) and is acylated with the appropriate anhydride of isobutyric acid, iodoacetic acid and 1-naphthylacetic acid respectively, to yield:
    • [Ibu0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 7
    • [IAc0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 8
    • [Nac0-Glu1,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2   Peptide 9
  • EXAMPLE VI
  • [0072]
    The synthesis of Peptide 10 having the formula:
    • Ibu0-His1-D-Arg2-Asp3-Ala4-Ile5-Tpi6-Thr7-Asn8-Ser9-Tyr10-Arg11-Lys12-Val13-Leu14-Abu15-Gln16-Leu17-Ser18-Ala19-Arg20-Lys21-Leu22-Leu23-Gln24-Asp25-Ile26-Nle27-Ser28-Arg29-NH2
    or [Ibu0-His1,D-Arg2,Tpi6,Abu15,Nle27]hGH-RH(1-29)NH2 is conducted in a stepwise manner using manual solid phase peptide synthesis equipment. Benzhydrylamine (BHA) resin (Bachem, California) (200 mg, 0.11 mmole) is neutralized with 5 % DIEA in CH2Cl2 and washed according to the protocol described in Table I. The solution of Boc-Arg(Tos)-OH (141 mg, 0.33 mmole) in CH2Cl2-DMF (1:1) is shaken with the neutralized resin and DIC (60 µL, 0.37 mmole) in a manual solid phase peptide synthesis equipment for 1 hour. After the coupling reaction is proved to be complete by negative ninhydrin test, deprotection with 50% TFA in CH2Cl2, and neutralization with 5% DIEA in CH2Cl2, the peptide chain is built by stepwise addition of the following protected amino acids in the indicated order on the resin to obtain the desired peptide sequence:
    • Boc-Ser(Bzl)-OH, Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Tyr(2,6-diCl-Z)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Tpi-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Arg(Tos)OH,and Boc-His(Bom)-OH.
  • [0073]
    The protected amino acids (0.33 mmole each) are coupled with DIC (57 µL, 0.36 mmole) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters and Boc-Tpi-OH which was coupled by using BOP coupling method. After removal of the Boc protecting group from the alpha amino group of His1, the peptide is acylated using the symmetrical anhydride method. This is performed by reacting isobutyric acid (59 mg, 0.66 mmole) with DIC (60µl, 0.37 mmole) to form the symmetrical anhydride thereof, and reacting this anhydride with the peptide.
  • [0074]
    In order to cleave the peptide from the resin and deprotect it, the dried peptide resin (300-350 mg) is stirred with 0.5 mL m-cresol and 5 mL hydrogen fluoride (HF) at 0°C for 1 hour. After evaporation of the HF under vacuum, the remnant is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, approximately 150 mg crude product is obtained.
  • [0075]
    The crude peptide is purified (60 mg of the substance being purified by RP-HPLC using the same procedure and equipments described in Example V), then checked by analytical HPLC. The product is judged to be substantially (>95%) pure by analytical HPLC. Confirmation of the structure is provided by amino acid analysis.
  • EXAMPLE VII
  • [0076]
    The synthesis of Peptide 18 having the formula:
    • Nac0-Tyr1-D-Arg2-Asp3-Ala4-Ile5-Phe(pCl)6-Thr7-Asn8-Ser9-Tyr10-Arg11-Lys12-Val13-Leu14-Abu15-Gln16-Leu17-Ser18-Ala19-Arg20-Lys21-Leu22-Leu23-Gln24-Asp25-Ile26-Nle27-Ser28-Agm29
    or [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm, is conducted in a stepwise manner using manual solid phase peptide synthesis equipment.
  • [0077]
    Boc-Agm-SPA-aminomethyl resin (California Peptide Co., Inc., California) (200 mg, 0.06 mmole) is deprotected with 50% TFA in CH2Cl2, neutralized with 5% DIEA in CH2Cl2, and washed as described in Table I. A solution of Boc-Ser(Bzl)-OH (55 mg, 0.18 mmole) in CH2Cl2 is shaken with the H-Agm-SPA-aminomethyl resin and DIC (31 µl, 0.2 mmole) in a manual solid phase peptide synthesis equipment for 1 hour. After wash and performance of the ninhydrin reaction to check for completeness of coupling, the cycle is repeated in a manner as described in Table I to build the peptide chain step-wise by adding the following protected amino acids in the indicated order on the resin:
    • Boc-Nle-OH, Boc-Ile-OH, Boc-Asp(OcHx)-OH, Boc-Gln-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Ala-OH, Boc-Ser(Bzl)-OH, Boc-Leu-OH, Boc-Gln-OH, Boc-Abu-OH, Boc-Leu-OH, Boc-Val-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Arg(Tos)OH, Boc-Tyr(2,6-diCl-Z)-OH, Boc-Ser(Bzl)-OH, Boc-Asn-OH, Boc-Thr(Bzl)-OH, Boc-Phe(pCl)-OH, Boc-Ile-OH, Boc-Ala-OH, Boc-Asp(OcHx)-OH, Boc-D-Arg(Tos)OH, and Boc-Tyr(2,6-diCl-Z)-OH.
  • [0078]
    The protected amino acids (0.18 mmole each) are coupled with DIC (31 µl, 0.2 mmole) with the exceptions of Boc-Asn-OH and Boc-Gln-OH which are coupled with their preformed HOBt esters. After removal of the Boc protecting group from the alpha amino group of Tyr1, the peptide is acylated by the symmetrical anhydride method. In this method, the symmetrical anhydride of 1-naphthylacetic acid is formed by reacting 123 mg (or 0.66 mmole) of 1-naphthylacetic acid with 60 µl (0.37 mmole) DIC; the resulting symmetrical anhydride is reacted with the peptide.
  • [0079]
    In order to cleave the peptide from the resin and deprotect it, the dried peptide resin (210 mg) is stirred with 0.5 ml m-cresol and 5 ml hydrogen fluoride (HF) at 0°C for 1 hour. After evaporation of the HF under vacuum, the remnant is washed with dry diethyl ether and ethyl acetate. The cleaved and deprotected peptide is dissolved in 50% acetic acid and separated from the resin by filtration. After dilution with water and lyophilization, 54 mg crude product is obtained.
  • [0080]
    60 mg of the GH-RH antagonist peptide is dissolved in AcOH/H2O) and purified by RP-HPLC using the same procedure and equipments described in Example V. The product is judged to be substantially (>95%) pure by analytical HPLC. Rt = 13.52 min and k' = 0.819 (isocratic elution with 52% B). Confirmation of the structure is provided by amino acid analysis.
  • [0081]
    Peptide 19 is synthesized in the same manner as Peptide 18 except that it is acylated with the appropriate anhydride of isobutyric acid in place of Nac, to yield:
    • [Ibu0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 19
  • [0082]
    Peptide 32 is synthesized in the same manner as Peptide 18 except that Boc-Phe(pCl)-OH6 is replaced with Boc-Nal-OH6 to yield:
    • [Nac0,D-Arg2,Nal6,Abu15,Nle27]hGH-RH(1-28)Agm   Peptide 32.
  • [0083]
    Peptide 34 is synthesized in the same manner as Peptide 18 except that Boc-D-Arg(Tos)-OH2 is replaced with Boc-D-Cit-OH2, to yield:
    • [Nac0,D-Cit2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm.
  • [0084]
    Peptide 35 is synthesized in the same manner as Peptide 34 except that acylation with the anhydride of 1-naphthylacetic acid is omitted to yield:
    • [D-Cit2,Phe(pCl)6, Abu15,Nle27]hGH-RH(1-28)Agm.
  • [0085]
    Peptide 36 is synthesized in the same manner as Peptide 34 except that Boc-Phe(pCl)-OH6 is replaced with Boc-Nal-OH respectively, to yield:
    • [Nac0,D-Cit2,Nal6,Abu15,Nle27]hGH-RH(1-28)Agm.
  • [0086]
    Peptide 37 is synthesized in the same manner as Peptide 18 except that after removal of the Boc protecting group from the alpha amino group of Tyr1, the peptide is not acylated.
  • EXAMPLE VIII
  • [0087]
    • Biological ActivityThe peptides of the present invention were tested in an in vitro and in vivo assay for their ability to inhibit the hGH-RH(1-29)NH2 induced GH release.
    • Superfused Rat Pituitary System. The analogues were tested in vitro in a test described earlier (S. Vigh and A.V. Schally, Peptides 5:241-347, 1984) with modification (Z. Rekasi and A.V. Schally, P.N.A.S. 90:2146-2149, 1993). Briefly, the cells are preincubated with peptides for 9 minutes (3mL) at yarious concentrations. Immediately after the incubation, 1 nM hGH-RH(1-29)NH2 is administered for 3 minutes (1mL) [0 minute response]. To check the duration of the antagonistic effect of the analogue, 1 nM hGH-RH(1-29)NH2 is applied 30, 60, 90, and 120 minutes later for 3 minutes [30, 60, 90, 120 min responses]. Net integral values of the GH responses are evaluated. GH responses are compared to and expressed as percent of the original GH response induced by 1 nM GH-RH(1-29)NH2. The effect of the new antagonists are compared to that of [Ac-Tyr1,D-Arg2]hGH-RH(1-29)NH2, the "Standard antagonist".
    • Growth Hormone Radio-immunoassay. Rat GH levels in aliquots of undiluted and diluted superfusion samples were measured by double-antibody radioimmunoassay using materials supplied by the National Hormone and Pituitary Program, Baltimore, Maryland. The results of RIA were analyzed with a computer program developed in our institute (V. Csernus and A.V. Schally, Harwood Academic (Greenstein, B.C. ed., London, pp. 71-109, 1991), hereby incorporated by reference. Inter-assay variation was less than 15% and intra-assay variation was less than 10%.
    • GH-RH Binding Assay. A sensitive radioreceptor binding assay was developed to determine the binding characteristics of the antagonists of GH-RH (G. Halmos, A.V. Schally et al., Receptor 3, 87-97, 1993), hereby incorporated by reference. The assay is based on binding of labelled [His1,Nle27]hGH-RH(1-32)NH2 to rat anterior pituitary membrane homogenates. Iodinated derivatives of [His1,Nle27]hGH-RH(1-32)NH2 are prepared by the chloramine-T method (F.C. Greenwood et al., Biochemistry 89:114-123, 1963). Pituitaries from male Sprague-Dawley rats (250-300 g) are used to prepare crude membranes. For saturation binding analyses, membrane homogenates are incubated with at least 6 concentrations of [His1,125I-Tyr10,Nle27]hGH-RH(1-32) NH2, ranging from 0.005 to 0.35 nM in the presence or absence of excess unlabelled peptide (1 µM). The pellet is counted for radioactivity in a γ-counter. The affinities of the antagonist peptides tested to rat pituitary GH-RH receptors are determined in competitive binding experiments. The final binding affinities are estimated by Ki (dissociation constant of the inhibitor-receptor complex) and are determined by the Ligand PC computer program of Munson and Rodbard as modified by McPherson. Relative affinities compared to [Ac-Tyr1,D-Arg2]hGH-RH(1-29)NH2, the Standard antagonist, are calculated as the ratio of Ki of the tested GH-RH antagonist to the Ki of the Standard antagonist.
    • In Vivo Tests. Adult male Sprague-Dawley rats are anesthetized with pentobarbital (6mg/100g b.w., i.p.). Blood samples are taken from the jugular vein 30 min after the injection of pentobarbital. One group of 7 animals receives hGH-RH(1-29)NH2 as control. Other groups of rats are injected with [Ac-Tyr1,D-Arg2]hGH-RH(1-29) NH2 as Standard antagonist, or with one of the antagonist peptide 30 seconds prior to hGH-RH (1-29)NH2, which is administered at dose of 2-3 µg/kg b.w. Blood samples are taken from the jugular vein 5 and 15 min after the injection of antagonists. GH levels are measured by RIA. Potencies of the antagonists are calculated by the factorial analysis of Bliss and Marks with 95% confidence limits and are based on the doses of 100 and 400 µg/kg b.w. of the Standard antagonist and 20 and 80 µg/kg b.w. of the antagonists tested. Statistical significance was assessed by Duncan's new multiple range test.
    • Results in vitro. The results of the in vitro antagonistic activities tested in superfused rat pituitary system and binding assay are summarized in Table II and Table III, respectively. As can be seen from these data, acylation of the analogues with Nac or Ibu which contain D-Arg2 or D-Cit2 substitution combined with Phe(pCl)6 or Nal6, Abu15, Nle27, and Agm29 cause an immense increase in receptor binding as well as in inhibition of GH release in vitro. Antagonist peptides [Nac0,D-Arg2,pCl-Phe6,Abu15, Nle27] hGH-RH(1-29)NH2 (Peptide 1), [Nac0-His1,D-Arg2,Phe(pCl)6,Abu15, Nle27] hGH-RH(1-29)NH2 (Peptide 5), Ibu0,D-Arg2,Phe (pCl)6,Abu15,Nle27] hGH-RH(1-28)Agm (Peptide 19) and [Nac0, D-Arg2, pCl-Phe6,Abu15, Nle27] hGH-RH(1-28)Agm (Peptide 18) are the most effective antagonists in vitro. Peptides 1 and 18 are also extremely long acting in vitro: the inhibition of GH release is 90% (30 nM dose) of the control value 4.5 hours after the incubation in case of Peptide 1; and the inhibition of GH release by Peptide 18 is about 96% (30 nM dose) and 48% (3 nM dose) of the control value even 4.5 and 6 hours after the incubation, respectively. The receptor binding affinities of analogues Peptides 1, 5, and 19 are 82.56, 67.08, and 26.18 times greater respectively than that of the standard GH-RH antagonist.
    • Results in vivo. Table IV shows the serum GH levels in rats pretreated with GH-RH antagonists. Peptides 1 and 19 produce a significant greater and longer-lasting inhibition of the GH response to hGH-RH(1-29)NH2 than the standard antagonist. In vivo experiments, Peptide 19 inhibits hGH-RH(1-29)NH2-induced GH-release to greater extent and for a longer period of time than Peptide 1.
    Inhibition of GH Release in Superfused Rat Pituitary System
    Peptide Dose (nM) Inhibition of GH release (%)
    0 min 30 min 60 min 120 min
    Standard antagonist: 100 62.1 2.5 19
    1 100 23.3 93.9 89.3
    30 96.1 95 92.1 88.8
    10 90.3 90 87.1 83.1
    3 18.1 31.5 17.1
    3 30 80.7 16.4 0
    5 30 92.6 86.4 81.4 64.5
    7 100 73.9 25 45
    10 14.2 20.8 51.6
    8 30 59.1 0 7.3 14
    9 100 90.7 79.5 76
    30 88.4 46.5 43.9 32.1
    10 300 2.5 21.5
    100 29.4 49.7
    18 30 83.6 93.9 89.3 98.9
    10 96.6 97.2 97.1 90.0
    3 77.6 83.4 75.3 58.8
    1 56.3 56.7 41.3 45.8
    0.3 11.0 45.0 15.6 13.5
    19 100 95 74.7 36.7
    30 82.7 40.7 9.6
    10 70 18.2 13.9
    3 62 16.4
    32 30 87.3 88.3 75.9 71.8
    3 35.9 37.1 43.4
    34 30 91.2 87.4 84.8
    3 70.4 50.5 40.6
    35 30 59.3 39.5 22.3
    37 30 97.5 67.3 58.4 62.1
    3 78.5 38.8
    Ki values and relative affinities (R.A) of hGH-RH antagonists
    Peptide K i (nM) R.A.
    Standard 3.22 ± 0.12 1
    1 0.04 ± 0.01 82.56
    5 0.05 ± 0.01 67.08
    7 1.35 ± 0.02 2.39
    8 0.91 ± 0.01 3.54
    9 0.87 ± 0.1 3.72
    19 0.12 ± 0.04 26.18
    Serum Growth Hormone Levels in Rats Pretreated with Different GH-RH Antagonists 5 Minutes Prior to Stimulation with GH-RH(1-29)NH2
    Treatment (intravenously) Dose (µg/kg) GH Levels (ng/mL) POTENCY (measured against the Standard Antagonist)
    Saline 89.0 ± 17.7
    GH-RH(1-29)NH2 3.0 956.7 ± 113.6
    Standard antagonist 100.0 738.3 ± 34.7
    400.0 439.7 ± 47.3
    Peptide 19 20.0 451.8 ± 42.2
    80.0 155.0 ± 38.2
    18.90
    95% Limits - 11.0-32.47
    Peptide 1 20.0 641.2 ± 81.4
    80.0 470.0 ± 46.1
    6.09
    95% Limits - 3.11-11.96
  • EXAMPLE IX
  • [0088]
    The experiment of Example VIII is repeated to evaluate the efficacy and duration of effect of GH-RH antagonist Peptide 18 in suppressing GH-RH(1-29)-stimulated serum growth hormone release in rats. Male Sprague-Dawley rats weighing 300-350 g were anesthetized with sodium pentobarbital (50mg/kg b.w.) and half of the initial pentobarbital dosage was given at 45 min intervals to maintain anesthesia. Twenty minutes after injection of pentobarbital, GH-RH antagonist Peptide 18 was administered intravenously in a dose of 80 µg/kg b.w. to the rats (0 time). Nine rats were used in each group. In order to stimulate GH release, bolus iv injections of GH-RH(1-29)NH2 at a dose of 3µg/kg b.w. were given at 0 time and at 30 min after administration of the GH-RH antagonists. Blood samples were taken from the jugular vein 5 min after GH-RH(1-29)NH2 injections. Serum GH levels were measured by radio-immunoassay. Statistical significance was assessed by Duncan's new multiple range test. The results of this experiment are shown in Table V.
    Serum Growth Hormone Levels in Rats Pretreated with GH-RH Antagonist Peptide 18 5 minutes prior to stimulation with GH-RH(1-29)NH2 at a dose of 3µg/kg
    Pretreatment (intravenously) Dose (µg/kg) GH Levels (ng/ml)
    Saline 10.6 ± 0.02
    GH-RH(1-29)NH2 3.0 1650.6 ± 182.7
    Peptide 18 80.0 1231.3 ± 81.3
  • [0089]
    GH-RH antagonist Peptide 18 injected at a dose of 80µg/kg inhibited GH-RH(1-29)NH2-induced GH secretion by about 24% 5 minutes after its administration.
  • EXAMPLE X Investigation of the Effect of Peptide 19 on the Growth of Human Osteosarcoma Cell Lines SK-ES-1 and MMNG/HOS Transplanted Athymic Nude Mice or Cultured In Vitro.
  • [0090]
    • Methods: Male athymic nude mice bearing subcutaneously implanted Peptide 19 and MNNG/HOS tumors were treated for 4 and 3 weeks, respectively, with Peptide 19 administered from osmotic minipumps at a dose of 40µg/animal/day. Tumor volume and weight, mitotic index, apoptosis and Bromodeoxyuridine (BUdR) labeling index, an indicator of tumor cell proliferation were determined. The effect of Peptide 19 on IGF-I levels in serum, tumor and liver tissue were measured. Concentration of receptors of IGF-I was determined in tumor membrane fractions of both osteosarcomas. In addition, direct effects of Peptide 19 on DNA synthesis and proliferation of SK-ES-1 a nd MNNG/HOS cells, as well as on the secretion of IGF-I by these cell lines were evaluated in cell cultures.
    • Results: Growth of both osteosarcomas in nude mice was significantly inhibited by Peptide 19 (Figs.1 and 2). Growth inhibition of SK-ES-1 and MNNG/HOS tumors were reflected by a reduction in tumor volume of 64% and 49%, and a reduction in tumor weight of 62% and 47% respectively, after treatment with Peptide 19. Therapy with Peptide 19 also decreased tumors by 76% as measured by specific RIA. Receptor analyses demonstrated high affinity binding sites for IGF-I on membranes of both tumors. The concentration of IGF-I in liver tissue of nude mice not bearing tumors injected daily for 5 days with Peptide 19 was decreased by about 40% as compared to that in untreated animals. In cell cultures, the proliferation of SK-ES-1 and MNNG/HOS cells, as well as the [3H]thymidine incorporation into the DNA of both cell lines were strongly inhibited by antagonist Peptide 19. The GH-RH antagonist also markedly reduced the autocrine secretion of IGF-I by both cell lines in vitro.
  • EXAMPLE XI Study of the Effects of Peptide 19 on MXT Estrogen Independent Mouse Mammary Tumors
  • [0091]
    Female BDF mice were transplanted with 1mm 3 pieces of an MXT (3.2) estrogen independent breast cancer. Treatment with Peptide 19 started one day after transplantation as follows:
    0.8µg/day s.c. once daily 5 mice
    3.2µg/day s.c. once daily 5 mice
  • [0092]
    Tumor volume was measured on day 10, 14 and 18. The results are shown on the graph (Fig. 3). Antagonist Peptide 19 at either dose significantly inhibited the growth of breast cancer in mice.
  • EXAMPLE XII Long Acting intramuscular injectable formulation (Sesame Oil Gel)
  • [0093]
    [Nac0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2 (Peptide 1) 10.0 mg
    Aluminum monostearate, USP 20.0 mg
    Sesame oil g.s. ad 1.0 ml
  • [0094]
    The aluminum monostearate is combined with the sesame oil and heated to 125°C with stirring until a clear yellow solution forms. This mixture is then autoclaved for sterility and allowed to cool. The hGH-RH antagonist Peptide 1 is then added aseptically with trituration. Particularly preferred antagonists are salts of low solubility, e.g., pamoate salts and the like. These exhibit long duration of activity.
  • EXAMPLE XIII Aqueous Solution for Intramuscular Injection
  • [0095]
    [Nac0,His1-D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-29)NH2 (Peptide 5) 500 mg
    Gelatin, nonantigenic 5 mg
    Water for injection g.s. ad 100 ml
  • [0096]
    The gelatin and GHRH antagonist Peptide 19 are dissolved in water for injection, then the solution is sterile filtered.
  • EXAMPLE XIV
  • [0097]
    Long Acting IM Injectable-Biodegradable Polymer Microcapsules Microcapsules are made from the following:
    25/75 glycolide/lactide copolymer (0.5 intrinsic viscosity) 99%
    [Ibu0,D-Arg2,Phe(pCl)6,Abu15,Nle27]hGH-RH(1-28)Agm29 (Peptide 19) 1%
  • [0098]
    25 mg of the above microcapsules are suspended in 1.0 ml of the following vehicle:
    Dextrose 5.0%
    CMC, sodium 0.5%
    Benzyl alcohol 0.9%
    Tween 80 0.1%
    Water, purified q.s. 100.0%
  • [0099]
    The test results described herein are generally considered by those skilled in the art to be predictive of results in humans.
Classificações
Classificação internacionalA61P3/00, C07K14/60, A61K38/04, A61P3/10, A61P3/08, A61K38/00, A61P5/00, A61P13/02, A61P35/00, A61P27/02, A61P15/00
Classificação cooperativaA61K38/00, C07K14/60
Classificação europeiaC07K14/60
Eventos legais
DataCódigoEventoDescrição
31 dez. 2007BEREBe: lapsed
Owner name: THE *ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Effective date: 20041130
16 fev. 2006REGReference to a national code
Ref country code: ES
Ref legal event code: FD2A
Effective date: 20041129
28 nov. 2005PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: IT
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20051128
2 set. 2005REGReference to a national code
Ref country code: FR
Ref legal event code: ST
24 ago. 2005REGReference to a national code
Ref country code: IE
Ref legal event code: MM4A
1 ago. 2005NLV4Nl: lapsed or anulled due to non-payment of the annual fee
Effective date: 20050601
29 jul. 2005REGReference to a national code
Ref country code: PT
Ref legal event code: MM4A
Effective date: 20050530
29 jul. 2005PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: FR
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20050729
20 jul. 2005GBPCGb: european patent ceased through non-payment of renewal fee
Effective date: 20041128
15 jul. 2005REGReference to a national code
Ref country code: CH
Ref legal event code: PL
5 jul. 2005EUGSe: european patent has lapsed
27 jun. 2005REGReference to a national code
Ref country code: DK
Ref legal event code: EBP
2 jun. 2005PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: GR
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20050602
1 jun. 2005PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: DE
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20050601
Ref country code: NL
31 maio 2005BEREBe: lapsed
Owner name: THE *ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Effective date: 20041130
30 maio 2005PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: PT
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20050530
30 nov. 2004PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: BE
Ref country code: CH
Ref country code: DK
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20041130
Ref country code: LI
29 nov. 2004PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: ES
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20041129
Ref country code: IE
Ref country code: SE
28 nov. 2004PG25Lapsed in a contracting state announced via postgrant inform. from nat. office to epo
Ref country code: GB
Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES
Effective date: 20041128
9 dez. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: BE
Payment date: 20031209
Year of fee payment: 10
19 nov. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: ES
Payment date: 20031119
Year of fee payment: 10
7 nov. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: FR
Payment date: 20031107
Year of fee payment: 10
4 nov. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: DK
Payment date: 20031104
Year of fee payment: 10
3 nov. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: DE
Ref country code: SE
Payment date: 20031103
Year of fee payment: 10
31 out. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: IE
Payment date: 20031031
Year of fee payment: 10
30 out. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: CH
Ref country code: NL
Payment date: 20031030
Year of fee payment: 10
29 out. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: GB
Payment date: 20031029
Year of fee payment: 10
Ref country code: GR
23 out. 2003PGFPPostgrant: annual fees paid to national office
Ref country code: PT
Payment date: 20031023
Year of fee payment: 10
11 jan. 2002REGReference to a national code
Ref country code: FR
Ref legal event code: RN
Ref legal event code: FC
1 jan. 2002REGReference to a national code
Ref country code: GB
Ref legal event code: IF02
2 nov. 2001REGReference to a national code
Ref country code: FR
Ref legal event code: ST
31 out. 200126NNo opposition filed
30 abr. 2001REGReference to a national code
Ref country code: PT
Ref legal event code: SC4A
Free format text: AVAILABILITY OF NATIONAL TRANSLATION
Effective date: 20010109
15 fev. 2001REGReference to a national code
Ref country code: CH
Ref legal event code: NV
Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS
12 fev. 2001REGReference to a national code
Ref country code: DK
Ref legal event code: T3
9 fev. 2001ETFr: translation filed
1 fev. 2001REGReference to a national code
Ref country code: ES
Ref legal event code: FG2A
Ref document number: 2152380
Country of ref document: ES
Kind code of ref document: T3
Format of ref document f/p: P
19 jan. 2001ITFIt: translation for a ep patent filed
Owner name: CON LOR S.R.L.
14 dez. 2000REFCorresponds to:
Ref document number: 69426270
Country of ref document: DE
Date of ref document: 20001214
Format of ref document f/p: P
13 dez. 2000REGReference to a national code
Ref country code: IE
Ref legal event code: FG4D
15 nov. 2000REGReference to a national code
Ref country code: CH
Ref legal event code: EP
8 nov. 2000AKDesignated contracting states:
Kind code of ref document: B1
Designated state(s): BE CH DE DK ES FR GB GR IE IT LI NL PT SE
15 dez. 1999RTI1Title (correction)
Free format text: ANALOGUES OF HGH-RH (1-29)NH2 HAVING ANTAGONISTIC ACTIVITY
8 dez. 1999RTI1Title (correction)
Free format text: ANALOGUES OF HGH-RH (1-29)NH2 HAVING ANTAGONISTIC ACTIVITY
23 set. 199817QFirst examination report
Effective date: 19980810
9 out. 1996RBVDesignated contracting states (correction):
Designated state(s): BE CH DE DK ES FR GB GR IE IT LI NL PT SE
2 out. 1996AKDesignated contracting states:
Kind code of ref document: A1
Designated state(s): BE CH DE DK ES FR GB GR IE IT LI NL PT SE
2 out. 199617PRequest for examination filed
Effective date: 19960716